Loading resource…

Elsevier
Gliclazide remains a preferred option among sulfonylureas for managing type 2 diabetes due to its proven efficacy and safety profile. The document reviews evidence from various studies, including the ADVANCE trial, which supports gliclazide's glycemic control and microvascular benefits. It also addresses the pharmacologic selectivity of gliclazide and its implications for clinical practice, emphasizing the need for further pharmacoeconomic research to validate its relevance in real-world diabetes care.
No account needed